Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Law firms continue to sell clients on international footprints, but sprawling office networks count for little if financial structures discourage internal collaboration
A&O Shearman and Fish & Richardson invested in German talent, meanwhile, major firms have assembled for an on the merits case pitting KeeeX against OpenAI and Adobe